CCDTR Core Members and Staff participated in the 5K@ADA on Sunday, June 9, 2019. Through Novo Nordisk’s continued support of the American Diabetes Association, the 5K@ADA in San Francisco was free of charge to registered 79th Scientific Sessions attendees.
As a community activity that encourages healthy exercise and promotes diabetes awareness,1,214 people completed the 5K@ADA and helped set the pace for living a healthier lifestyle by running or walking in San Francisco.
Elbert Huang, MD, Core Member of the CCDTR, along with colleagues has published a new paper in Diabetes Care, entitled ‘Cost-Effectiveness of Shared Telemedicine Appointments in Young Adults With T1D: CoYoT1 Trial’.
Young adults (YAs) with type 1 diabetes (T1D) often struggle to achieve glycemic control and maintain routine clinic visits. This study aimed to evaluate the societal cost-effectiveness of the Colorado YAs with T1D (CoYoT1) Clinic, an innovative care model of shared medical appointments through home telehealth.
Within the trial, there were no significant differences found in 9-month quality-adjusted life; however, the control group had a larger decline from baseline in utility than the CoYoT1 group, indicating a quality of life (QoL) benefit of the intervention (difference in difference mean ± SD: 0.04 ± 0.09; P = 0.03). There was no significant difference in total costs. The CoYoT1 group had more study-related visits but fewer nonstudy office visits and hospitalizations. The CoYoT1 care model may help YAs with T1D maintain a higher QoL with no increase in costs.
Neda Laiteerapong, MD, MS, Associate Director of Clinical Outcomes for the Center for Chronic Disease Research and Policy, has published an editorial with Kasia Lipska, MD, MHS, in the New England Journal of Medicine concerning the lack of glycemic legacy effects in the Veterans Affairs Diabetes Trial (VADT). The VADT included 1791 military veterans who had received a diagnosis of type 2 diabetes a mean of 11.5 years earlier and who had been randomly assigned to intensive or standard glucose control for a median of 5.6 years. A major implication of the VADT follow-up study is that older patients with advanced diabetes should not expect long-term cardiovascular benefits from intensive glycemic control. Instead, interventions that clearly reduce cardiovascular risk — such as smoking cessation, blood-pressure control, statin therapy, use of antiplatelet agents, and the use of glucose-lowering agents with proven cardiovascular benefits in patients with established cardiovascular disease — should be prioritized.